Your fact-checks will appear here
Class of pharmaceutical drugs
Bydureon (exenatide extended‑release) is a once‑weekly injectable GLP‑1 receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes in adults and certai...
Dual GIP/GLP‑1 agonists like tirzepatide reduce weight and improve multiple cardiometabolic risk factors that plausibly lower heart‑failure events in obese patients, particularly HFpEF, via hemodynami...
Randomized trials and pooled analyses show semaglutide delivers larger average reductions in HbA1c and body weight than many other GLP‑1 receptor agonists (GLP‑1RAs), with head‑to‑head meta‑analysis f...